NASDAQ: SCLXScilex Holding Co Stock
$6.02-0.10 (-1.63%)
Updated Apr 17, 2025
SCLX Price
$6.02
Fair Value Price
N/A
Market Cap
$41.85M
52 Week Low
$5.80
52 Week High
$80.50
P/E
-0.31x
P/B
-0.22x
P/S
0.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$56.59M
Earnings
-$72.81M
Gross Margin
70.5%
Operating Margin
-125.19%
Profit Margin
-128.7%
Debt to Equity
-1.48
Operating Cash Flow
$19M
Beta
0.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SCLX Overview
Vickers Vantage Corporation I is a "blank check" company formed to effect mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar combinations with one or more businesses. The company has not publicly identified its target sectors. The company was incorporated in 2020 and is headquartered in Singapore.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SCLX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
SCLX
Ranked#16 of 18
Ranked#16 of 18
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $104.54 | A | |
| $78.00 | A | |
| $110.86 | A |
Be the first to know about important SCLX news, forecast changes, insider trades & much more!
SCLX News
Overview
Due Diligence Score
–
Industry Average (38)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SCLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SCLX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SCLX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
SCLX's Earnings (EBIT) of -$70.85M... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more SCLX due diligence checks available for Premium users.
Valuation
SCLX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.31x
Industry
52.36x
Market
27.98x
SCLX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.22x
Industry
6.01x
SCLX's financial health
Profit margin
Revenue
$14.9M
Net Income
-$6.5M
Profit Margin
-43.4%
SCLX's Earnings (EBIT) of -$70.85M... subscribe to Premium to read more.
Interest Coverage Financials
SCLX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$93.0M
Liabilities
$285.6M
Debt to equity
-1.48
SCLX's short-term liabilities ($259.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SCLX's short-term assets ($41.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SCLX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SCLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.5M
Investing
-$195.0k
Financing
-$7.2M
SCLX's operating cash flow ($19.35M)... subscribe to Premium to read more.
Debt Coverage Financials
SCLX vs General Drug Manufacturer Stocks
Scilex Holding Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.